Brokerage firm BTIG Research Downgrades its rating on OraSure Technologies(NASDAQ:OSUR). In a research note issued to the investors, the brokerage major Removes the price-target to $ per share. The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by BTIG Research was issued on Sep 19, 2016.
In a different note, On Aug 29, 2016, Stephens & Co. said it Upgrades its rating on OraSure Technologies. The shares have been rated ‘Overweight’ by the firm. On Aug 24, 2016, Canaccord Genuity said it Maintains its rating on OraSure Technologies. In the research note, the firm Raises the price-target to $7.00 per share. The shares have been rated ‘Buy’ by the firm. On Aug 4, 2016, Jefferies said it Maintains its rating on OraSure Technologies. In the research note, the firm Lowers the price-target to $8.50 per share. The shares have been rated ‘Buy’ by the firm.
OraSure Technologies (OSUR) remained unchanged at the close of Thursday session. Even as the volume increased to 8,29,286 ,the shares failed to make any impression and ended at 0 points or 0.00% at $8.49. The trading session commenced at $8.45 and the stock hit a high of $8.59 and touched $8.061 at the lower end. Considering that the stock pared all of the losses, it can be said as a positive sign. The share price has a 52-week high of $9.05 and the 52-week low is $4.39. The company has a market cap of $472 M and has approximately 5,56,00,580 outstanding shares.
OraSure Technologies(OSUR) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $31.36M. Analysts had an estimated revenue of $31.15M. Earnings per share were $0.07. Analysts had estimated an EPS of $0.05.
Several Insider Transactions has been reported to the SEC. On Aug 31, 2016, Jack E Jerrett (SVP & General Counsel) sold 68,686 shares at $8.52 per share price.Also, On Aug 31, 2016, Charles W Patrick (director) sold 26,308 shares at $8.25 per share price.
OraSure Technologies Inc. (OraSure) is involved in the development manufacture marketing and sale of oral fluid diagnostic products and specimen collection devices and other diagnostic products designed to detect or diagnose critical medical conditions. These products include OraQuick In-Home HIV Test OraQuick ADVANCE OraSure HIV-1 oral specimen collection device OraQuick HCV rapid antibody test Intercept oral fluid drug testing system OraSure QuickFlu Rapid Flu A&B Test and Q.E.D. Saliva Alcohol test. The Company also manufactures and sells a range of cryosurgical products. Through its wholly owned subsidiary DNA Genotek Inc. the Company provides oral fluid sample collection stabilization and preparation products for molecular diagnostic applications.